Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
“This company's losing so much money, I know, but it's Dr. Siegall… So therefore, if you want to speculate on it, fine. But we do not think that you're investing.” Pixabay/Public Domain Immunome, Inc. (NASDAQ:IMNM) is a clinical-stage biotech company that focuses on developing targeted cancer treatments, with a leading drug candidate in late-stage testing and another in early clinical trials. The company's pipeline also includes earlier-stage therapies aimed at treating solid tumors with more precise approaches. On December 15, 2025, it announced that the Phase 3 RINGSIDE trial of varegacestat showed strong results in patients with progressing desmoid tumors. The drug showed a reduction of risk of disease progression or death by 84% versus placebo. Additionally, it delivered a 56% response rate compared with 9% for placebo, and reduced tumor volume by 83%, and mostly only showed mild to moderate side effects. Immunome, Inc. (NASDAQ:IMNM) plans to submit a New Drug Application t
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals [Yahoo! Finance]Yahoo! Finance
- Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? [Yahoo! Finance]Yahoo! Finance
- Immunome (NASDAQ:IMNM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.MarketBeat
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 12/30/25 - Form 4
- 12/23/25 - Form 4
- 12/22/25 - Form SCHEDULE
- IMNM's page on the SEC website